Ignite Creation Date:
2025-12-24 @ 3:51 PM
Ignite Modification Date:
2026-01-20 @ 5:48 PM
Study NCT ID:
NCT02768792
Status:
COMPLETED
Last Update Posted:
2024-09-25
First Post:
2016-05-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-22
Start Date Type:
ACTUAL
Primary Completion Date:
2019-11-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-06-20
Completion Date Type:
ACTUAL
First Submit Date:
2016-05-05
First Submit QC Date:
None
Study First Post Date:
2016-05-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-07-02
Results First Submit QC Date:
None
Results First Post Date:
2021-09-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-10
Last Update Post Date:
2024-09-25
Last Update Post Date Type:
ACTUAL